

AMENDMENT TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the applications:

Listing of Claims:

1-6. (canceled)

7. (currently amended) A compound that binds to an mpl receptor comprising the structure

_____TMP₁-(L₁)_n-TMP₂

~~The compound according to Claim 1~~ wherein TMP₁ and TMP₂ are each

Ile-Glu-Gly-Pro-Thr-Leu-Arg-Gln-Trp-Leu-Ala-Ala-Arg-Ala. (SEQ ID NO: 1);

L₁ is a linker; and

_____n is 0 or 1;

and physiologically acceptable salts thereof.

8-15. (canceled)

16. (currently amended) A compound that binds to an mpl receptor

~~The compound according to Claim 1~~, which is selected from the group consisting of

IEGPTLRQWLAARA-GPNG-IEGPTLRQWLAARA

(SEQ. ID NO: 10)

IEGPTLRQCLAARA-GGGGGGGG-IEGPTLRQCLAARA (cyclic)	(SEQ. ID NO: 11)
<div style="border-bottom: 1px solid black; width: 300px; margin: 5px 0;"></div>	
IEGPTLRQCLAARA-GGGGGGGG-IEGPTLRQCLAARA (linear)	(SEQ. ID NO: 12)
IEGPTLRQALAARA-GGGGGGGG-IEGPTLRQALAARA	(SEQ. ID NO: 13)
IEGPTLRQWLAARA-GGGKGGGG-IEGPTLRQWLAARA	(SEQ. ID NO: 14)
IEGPTLRQWLAARA-GGGK(BrAc)GGGG-IEGPTLRQWLAARA	(SEQ. ID NO: 15)
IEGPTLRQWLAARA-GGGCGGGG-IEGPTLRQWLAARA	(SEQ. ID NO: 16)
IEGPTLRQWLAARA-GGGK(PEG)GGGG-IEGPTLRQWLAARA	(SEQ. ID NO: 17)
IEGPTLRQWLAARA-GGGC(PEG)GGGG-IEGPTLRQWLAARA	(SEQ. ID NO: 18)
IEGPTLRQWLAARA-GGGNGSGG-IEGPTLRQWLAARA	(SEQ. ID NO: 19)
IEGPTLRQWLAARA-GGGCGGGG-IEGPTLRQWLAARA	
<div style="border-bottom: 1px solid black; width: 300px; margin: 5px 0;"></div>	
IEGPTLRQWLAARA-GGGCGGGG-IEGPTLRQWLAARA	(SEQ. ID NO: 20);
IEGPTLRQWLAARA-GGGGGGGG-IEGPTLRQWLAARA	(SEQ. ID NO: 21).

17-23. (canceled)

24. (previously amended) A compound that binds to an mpl receptor, which is selected from the group consisting of

Fc-IEGPTLRQWLAARA-GPNG-IEGPTLRQWLAARA (SEQ. ID NO: 22)

Fc-IEGPTLRQWLAARA-GPNG-IEGPTLRQWLAARA-Fc (SEQ. ID NO: 23)

IEGPTLRQWLAARA-GGGGGGGG-IEGPTLRQWLAARA-Fc (SEQ. ID NO: 24)

Fc-GG-IEGPTLRQWLAARA-GPNG-IEGPTLRQWLAARA (SEQ. ID NO: 25)

Fc-IEGPTLRQWLAARA-GGGGGGGG-IEGPTLRQWLAARA (SEQ. ID NO: 26)

Fc-IEGPTLRQCLAARA-GGGGGGGG-IEGPTLRQCLAARA (cyclic)
|_____| (SEQ. ID NO: 27)

Fc-IEGPTLRQCLAARA-GGGGGGGG-IEGPTLRQCLAARA (linear) (SEQ. ID NO: 28)

Fc-IEGPTLRQALAARA-GGGGGGGG-IEGPTLRQALAARA (SEQ. ID NO: 29)

Fc-IEGPTLRQWLAARA-GGGKGGGG-IEGPTLRQWLAARA (SEQ. ID NO: 30)

Fc-IEGPTLRQWLAARA-GGGCGGGG-IEGPTLRQWLAARA (SEQ. ID NO: 31)

Fc-IEGPTLRQWLAARA-GGGNGSGG-IEGPTLRQWLAARA (SEQ. ID NO: 32)

Fc-IEGPTLRQWLAARA-GGGCGGGG-IEGPTLRQWLAARA

|

Fc-IEGPTLRQWLAARA-GGGCGGGG-IEGPTLRQWLAARA

(SEQ. ID NO: 33)

Fc-GGGGG-IEGPTLRQWLAARA-GGGGGGGG-IEGPTLRQWLAARA

(SEQ. ID NO: 34);

and physiologically acceptable salts thereof.

25-34. (canceled)